 |
|
Home | Recent Research Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN) |
 |
Recent Research Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)
|
 |
- May 18, 2015
-
A number of research firms have changed their ratings and price targets for BioMarin Pharmaceutical (NASDAQ: BMRN): 5/9/2015 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Piper Jaffray. They now have a $123.00 price target on the stock. 5/8/2015 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Jefferies Group. […]This article (Recent Research Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2015/05/18/recent-research-analysts-ratings-updates-for-biomarin-pharmaceutical-bmrn/
|
 |
|
 |
|
 |
